ClinicalTrials.gg
WithdrawnNCT01984606Updated Oct 27, 2014

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

A Phase 3 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
127th of 130
0 · median 79
Started
2015
with 4 others
Phase 3
28 of 130
1 open now
Registered
32nd of 130
by date
Lead sponsor
37 of 130
Boehringer Ingelheim

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 127th largest by enrollment, is one of 5 that started in 2015, is one of 28 in phase 3, and was the 32nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic control. The study will assess non-inferiority of empagliflozin to sitagliptin with regards to HbA1c.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

Inclusion criteria:

  • Diagnosis of type 2 diabetes mellitus.
  • Male and female patients on diet and exercise regimen who are:
  • Treatment-naïve, defined as absence of any oral antidiabetic therapy for 12 weeks prior to randomisation.

or

  • Pre-treated with immediate release metformin unchanged for 10 weeks prior to randomisation. Minimum dose for metformin: >=1500 mg/day or maximum tolerated dose or maximum dose according to local label.
  • of >= 7.5 % and \<= 10.5 % at Visit 1 and 3.
  • Age >= 18 yrs.

Exclusion criteria:

  • Uncontrolled hyperglycaemia with a glucose level >270 mg/dL (>15 mmol/L) after an overnight fast during dose stabilisation (if applicable) and/or placebo run-in.
  • Any other antidiabetic drug within 12 weeks prior to randomisation (applicable to treatment-naïve patients).
  • Any other antidiabetic drug within 10 weeks prior to randomisation except metformin (applicable to patients on background treatment with metformin).
  • Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or within 3 months prior to .
  • Indication of liver disease.
  • Moderate to severe renal impairment.
  • Bariatric surgery within the past two years.
  • Treatment with anti-obesity drugs 3 months prior to informed consent.
  • Current treatment with systemic at time of informed consent or any other uncontrolled endocrine disorder except type 2 diabetes mellitus.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Empagliflozin

    Empagliflozin once daily

    Drug: Empagliflozin · Drug: Placebo

  • Active comparator
    Sitagliptin

    Sitagliptin once daily

    Drug: Sitagliptin · Drug: Placebo

Interventions

  • Empagliflozin once daily

  • DrugPlacebo

    Placebo matching empagliflozin

  • Sitagliptin once daily

  • DrugPlacebo

    Placebo matching sitagliptin

06

What researchers measure

Primary outcomes

  1. The change from baseline in HbA1c after 52 weeks of treatment.

    Time frame: Baseline and week 52

Secondary outcomes

  1. The change in bodyweight (kg) from baseline after 52 weeks of treatment

    Time frame: Baseline and week 52

  2. The change in Systolic Blood Pressure (SBP) from baseline after 52 weeks of treatment

    Time frame: Baseline and week 52

  3. The coefficient of durability of HbA1c response between 24 weeks and 52 weeks of treatment

    Time frame: Week 24 and week 52

  4. The change in Diastolic Blood Pressure (DBP) from baseline after 52 weeks of treatment

    Time frame: Baseline and week 52

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2013
First posted
Nov 14, 2013
Start
Jan 2015
Primary completionEst.
Feb 2017
CompletionEst.
Feb 2017
Last update
Oct 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01984606
Responsible party
Sponsor
First posted
Nov 14, 2013
Start date
Jan 2015
Primary completion
Feb 2017 (estimated)
Completion
Feb 2017 (estimated)
Last update
Oct 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion